Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01577381 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01577381 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT01577381, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RN6G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01577381
The ClinicalTrials.gov registry entry for NCT01577381 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01577381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01577381 about?
NCT01577381 is a clinical study titled "Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration". The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
What is the current status of trial NCT01577381?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2012-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01577381?
The interventions under investigation include: Placebo (BIOLOGICAL), RN6G (BIOLOGICAL).
Who is sponsoring clinical trial NCT01577381?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.